Wave Life Sci Ord Sh (WVE) Stock Price, Quote & News

Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of...

Industry: Biotechnology

Sector: Healthcare

Phone: 65 6236 3388

Website: wavelifesciences.com

Address:

Marina One East Tower, 7 Straits View No.12-00, Singapore, Singapore

MulaBagz Apr. 1 at 2:39 PM

$WVE loading till $10+

0 · Reply

B_B_ Apr. 1 at 1:01 PM

$WVE I think there may be a power struggle between RA Capital and GSK, possibly with Shin Nippon siding with GSK, over the company’s strategic direction (potential deals or M&A activity). On March 23, Shin Nippon converted their preferred shares into ordinary shares with voting rights. Together, GSK and Shin Nippon would then hold nearly 28 million shares, surpassing RA Capital’s stake at that time. This likely prompted RA Capital to increase its holdings to 34 million shares a few days later. The top 6 shareholders own over 50% of the company’s shares.

1 · Reply

B_B_ Apr. 1 at 12:57 PM

$WVE Pharma Double-Dippers Lead Q1 Deal Activity to Nearly $47B April 1, 2026 Deal-hungry Big Pharmas, a long-sought biotech prize, an infrequent buyer and one serial biotech rabblerouser highlight a busy quarter in biopharma M&A. Eli Lilly has served up a triple-scoop of deals, while Gilead, GSK and Novartis went for more modest double-stacked cones in the first quarter. In all, biopharma spent about $46.8 billion on acquisitions in the period across 19 deals as M&A activity in the sector picks up. The period ended with a flurry of activity, including deals from Biogen, Eli Lilly and Novartis. All told, companies dropped about $20 billion on deals in the final week of the first period alone. … https://www.biospace.com/business/pharma-double-dippers-lead-q1-deal-activity-to-nearly-47b

0 · Reply

B_B_ Apr. 1 at 12:56 PM

$WVE Biotechs Are a Healthy Growth Bet. Thank M&A and New Drugs. By Paul R. La Monica March 31, 2026 Big Pharma companies are constantly searching for the next hot new drugs—and it’s often a lot easier to buy them than develop them. That’s great news for biotech investors. Merger activity is starting to heat up again in the sector. https://www.barrons.com/articles/biotech-stocks-etfs-38e6cb8e?gaa_at=eafs&gaa_n=AWEtsqfEEeGP9PTFBvIOaJZP4yhM-9o2UrNF92m-GjtKlFjSOwgvVGvd1Wyp&gaa_ts=69cd0ebe&gaa_sig=i_PoS8xiT06CnRU2XR-k9SZxjBd8BlP6g5CLspmlv2hTHNP8rk7gszJMQOGxaUYURhK0XIbBot_-HPdDTpfW3A%3D%3D

0 · Reply

Notnotshort Apr. 1 at 11:30 AM

$WVE Data from ARWR Phase 1/2a: ARO-INHBE Monotherapy: Visceral fat reductions (e.g., ~ -9.9% at week 16 single dose; -15.6% placebo-adjusted at week 24 with two doses) AROALK7 so far reduced visceral fat by 14.1% placebo adjusted at week 8 with 1 dosing. The big difference is that ARWR had patients with BMI range: 30–50 kg/m² (no average given AFAIK) vs BMI average of 32 for $WVE. The 30-50kg/m² group has more excessive fat they can lose compared to the lower BMI patients, so they respond with larger loses to drugs like these. $WVE said in their PR that they saw bigger declines in visceral fat with 400mg in those with higher visceral fat baseline. Its possible that they will have bigger visceral fat losses when they go for the same patient population as ARWR based on current data IMO

0 · Reply

Steppinstone Mar. 31 at 11:31 PM

$WVE WVE’s platform chemistry is so valuable. It can do more than ARWR and ALNY in terms of silencing and editing targets. WVE 007 is its first siRNA in the clinic and it has already shown 7 months of good efficacy with INHBE. WVE is already evaluating dimers and getting into extra hepatics. This is a really solid biotech with a great future IMO.

0 · Reply

Steppinstone Mar. 31 at 10:23 PM

$WVE This is a slow grind until news of FDA alignment with accelerated approval for WVE 006. With good news from the FDA, it could take a big junp. The recent selloff was so extreme and unwarranted, this one is ready to make a big jump with any type of good news.

0 · Reply

IGotYouRides Mar. 31 at 9:55 PM

$WVE I'm waiting for a Dip, it almost always comes before a rippp.....

1 · Reply

elmono Mar. 31 at 8:58 PM

$PEPG should see a large ass new RA Capital filing in 3-4 days…..$WVE style

1 · Reply

Nasfact Mar. 31 at 7:57 PM

$WVE interesting trading. Not peaking up immediately. Banks and funds want in cheap? 🧐

0 · Reply

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript

Mar 26, 2026, 3:00 PM EDT - 5 days ago

Wave Life Sciences stock crash: why analyst sees a buying opportunity

Mar 26, 2026, 11:25 AM EDT - 6 days ago

Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data?

Mar 26, 2026, 10:28 AM EDT - 6 days ago

WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 26, 2026, 9:33 AM EDT - 6 days ago

Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints

Mar 26, 2026, 7:30 AM EDT - 6 days ago

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

Mar 6, 2026, 11:33 AM EST - 25 days ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA RGNX

Mar 5, 2026, 8:30 AM EST - 27 days ago

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Feb 26, 2026, 3:57 PM EST - 4 weeks ago

Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 7:30 AM EST - 4 weeks ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 8:30 AM EST - 5 weeks ago

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 8:30 AM EST - 5 weeks ago

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

Feb 2, 2026, 2:16 PM EST - 2 months ago

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

GSK

Feb 2, 2026, 7:30 AM EST - 2 months ago

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

Jan 21, 2026, 12:40 PM EST - 2 months ago

MoneyShow's Best Investment Ideas For 2026: Part 9

GWW TGT TTD UFPT USAC VZ WLDN

Jan 13, 2026, 8:26 PM EST - 2 months ago

Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.

Jan 12, 2026, 7:30 AM EST - 2 months ago

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Jan 5, 2026, 8:30 AM EST - 3 months ago

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 6:30 AM EST - 3 months ago

Why Did Wave Life Sciences Surge 147%?

Dec 9, 2025, 9:50 PM EST - 4 months ago

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 9, 2025, 2:11 PM EST - 4 months ago

What's Going On With Wave Life Sciences Stock Tuesday?

Dec 8, 2025, 4:01 PM EST - 4 months ago

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 8, 2025, 3:17 PM EST - 4 months ago

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript

Dec 8, 2025, 7:30 AM EST - 4 months ago

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Dec 7, 2025, 4:00 PM EST - 4 months ago

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

Dec 5, 2025, 4:12 PM EST - 4 months ago

Wave Life Sciences: Being Realistic, There Is Still So Much To Prove

Nov 11, 2025, 11:46 AM EST - 5 months ago

These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results

Nov 10, 2025, 8:01 PM EST - 5 months ago

Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:30 AM EST - 5 months ago

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 8:30 AM EST - 5 months ago

Wave Life Sciences to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:30 PM EST - 5 months ago

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Nov 4, 2025, 8:30 AM EST - 5 months ago

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

Nov 1, 2025, 3:06 AM EDT - 5 months ago

Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript

Oct 29, 2025, 10:50 PM EDT - 5 months ago

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Oct 29, 2025, 4:15 PM EDT - 5 months ago

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Sep 18, 2025, 8:30 AM EDT - 6 months ago

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences

Sep 3, 2025, 3:10 PM EDT - 7 months ago

Wave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference Transcript

Sep 3, 2025, 1:28 PM EDT - 7 months ago

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

GSK

Sep 3, 2025, 7:30 AM EDT - 7 months ago

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Jul 30, 2025, 9:38 PM EDT - 8 months ago

Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:30 AM EDT - 8 months ago

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 8:30 AM EDT - 9 months ago

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

Jul 7, 2025, 5:42 PM EDT - 9 months ago

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

Jun 20, 2025, 4:01 PM EDT - 10 months ago

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

May 29, 2025, 8:30 AM EDT - 10 months ago

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 11 months ago

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 9, 2025, 4:57 PM EDT - 11 months ago

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:30 AM EDT - 11 months ago

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:30 AM EDT - 11 months ago

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

Mar 27, 2025, 3:54 PM EDT - 1 year ago

Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531

MulaBagz Apr. 1 at 2:39 PM

$WVE loading till $10+

0 · Reply

B_B_ Apr. 1 at 1:01 PM

1 · Reply

B_B_ Apr. 1 at 12:57 PM

0 · Reply

B_B_ Apr. 1 at 12:56 PM

0 · Reply

Notnotshort Apr. 1 at 11:30 AM

0 · Reply

Steppinstone Mar. 31 at 11:31 PM

0 · Reply

Steppinstone Mar. 31 at 10:23 PM

0 · Reply

IGotYouRides Mar. 31 at 9:55 PM

$WVE I'm waiting for a Dip, it almost always comes before a rippp.....

1 · Reply

elmono Mar. 31 at 8:58 PM

$PEPG should see a large ass new RA Capital filing in 3-4 days…..$WVE style

1 · Reply

Nasfact Mar. 31 at 7:57 PM

$WVE interesting trading. Not peaking up immediately. Banks and funds want in cheap? 🧐

0 · Reply

unbreakable01 Mar. 31 at 5:16 PM

$WVE bought in today, back to $10+ soon.

0 · Reply

B_B_ Mar. 31 at 4:49 PM

$WVE Iran President Says 'Prepared To End War' If Security Guarantees Offered, Oil Plunges by Tyler Durden Tuesday, Mar 31, 2026 https://www.zerohedge.com/markets/ramp-imminent-trump-tells-world-go-get-your-own-oil-strait-after-decimating-iran

0 · Reply

janed102 Mar. 31 at 4:32 PM

$WVE giving up all gains... What a shit show

1 · Reply

aquira Mar. 31 at 4:24 PM

$WVE what the actual fuck!!! From 7.8 to 7.08. The hell. Too much selling at this point.

1 · Reply

B_B_ Mar. 31 at 3:59 PM

$WVE Nasdaq recovered at exactly 11 am.

0 · Reply

IGotYouRides Mar. 31 at 2:42 PM

$WVE $750 to $2357 in a day on these calls told you it looked juicy yesterday

1 · Reply

aquira Mar. 31 at 2:25 PM

$WVE what's going on? Why going back down???

0 · Reply

B_B_ Mar. 31 at 1:51 PM

$WVE I think after around 11 am, the clouds will part and the sun will shine more brightly.

0 · Reply

BioRich Mar. 31 at 1:48 PM

$WVE So glad I got into this one. Looks like a massive winner already and showing no signs of slowing up. Congrats to those that bought the dip, and also to those that maintained their shares on the drop. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply

B_B_ Mar. 31 at 1:43 PM

$WVE Next catalysts, if Wave is not acquired in the coming weeks, are WVE-006 data in May and Arrowhead obesity data in June. Unlike Wave (average BMI 32), Arrowhead (BMI 30–50) has focused on higher-BMI subjects. ARO-INHBE and ARO-ALK7: We anticipate initial data for ARO-INHBE and ARO-ALK7 in January 2026 and a more complete look at the data toward the end of the second quarter of 2026. (*) Details of the late-breaking oral presentation: Title: RNA Editing for the Treatment of Alpha-1 Antitrypsin Deficiency … Date and time: Monday, May 18, 2026, 4:03 – 4:15 p.m. ET (**) (*) https://finance.yahoo.com/news/arwr-multiple-data-readouts-ahead-114800629.html (**) https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-acceptance-late-breaking-oral

0 · Reply

pal123 Mar. 31 at 1:43 PM

$APLS Check $WVE

0 · Reply

BocaDon Mar. 31 at 1:38 PM

$WVE so much room to go, we are in early, riding the up and down but definitely going to go up higher.

0 · Reply

Market Cap	1.25B
Revenue (ttm)	42.73M
Net Income (ttm)	-204.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-478.31%
Debt to Equity Ratio	0.00

Volume	12,407,801
Avg Vol	4,313,604
Day's Range	N/A - N/A
Shares Out	188.26M
Stochastic %K	29%
Beta	-1.77
Analysts	Strong Sell
Price Target	$27.57